Alexion Pharmaceuticals Reports Q1 Earnings

Alexion Pharmaceuticals Inc announced their quarterly earnings of $3.52 per share, beating the Zacks Consensus Estimate of $3.08 per share. This compares to earnings of $3.22 per share a year ago.

This quarterly report shows an earnings surprise of 14.29%. A quarter ago, it was expected that this drugmaker would post earnings of $2.50 per share when it produced earnings of $2.96, delivering a surprise of 18.40%. Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Alexion Pharmaceuticals Inc belongs to the Zacks Medical – Biomedical and Genetics industry posted revenues of $1.64 billion for the quarter ended March 2021, surpassing the Zacks Consensus Estimate by 4.49%. This compares to year-ago revenues of $1.44 billion. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock’s sudden price movement based on the recently-released numbers and forthcoming earnings expectations will mostly depend on management’s commentary on the earnings call. Alexion Pharmaceuticals Inc shares have added about 6% since the beginning of the year versus the S&P 500’s gain of 12.1%. The current consensus EPS estimate is $3.18 on $1.61 billion in revenues for the coming quarter and $12.86 on $6.51 billion in revenues for the current fiscal year. The company’s bottom line came in at $636.0 million, or $2.86 per share. This compares with $557.6 million, or $2.50 per share, in last year’s first quarter. The company’s revenue for the quarter rose 13.9% to $1.64 billion from $1.44 billion last year.